Recently, “SCLC-I” subtype, which is characterized by low expression of ASCL1, NEUROD1, and POU2F3 accompanied by an inflammatory gene signature, is considered to obtain the greatest benefit from immunochemotherapy10,11. This evidence concerns the gene NEUROD1 and small cell lung carcinoma.